Literature DB >> 1622406

Oligomeric tumour necrosis factor alpha slowly converts into inactive forms at bioactive levels.

A Corti1, G Fassina, F Marcucci, E Barbanti, G Cassani.   

Abstract

The stability of oligomeric human tumour necrasis factor alpha (TNF) at bioactive levels has been studied by two immunoenzymatic assays: one able to specifically detect oligomeric and not monomeric TNF (O-e.l.i.s.a.) and the other able to detect both forms (OM-e.l.i.s.a.). The selectivity of O-e.l.i.s.a. and OM-e.l.i.s.a. for oligomeric and monomeric TNF was demonstrated with isolated forms prepared by partial dissociation of recombinant TNF with 10% (v/v) dimethyl sulphoxide and gel-filtration h.p.l.c. Evidence for instability of oligomeric TNF were obtained in physiological buffers, as well as in serum and cell-culture supernatants, as a function of TNF concentration. In particular, only a half of the TNF antigen was recovered in the oligomeric form after 72 h incubation (37 degrees C) at 0.12 nM, whereas no apparent dissociation was detected at 4 nM. The structural changes observed at picomolar concentrations were rapidly reversed by raising the concentration of TNF to about 2 nM by ultrafiltration, suggesting that subunit dissociation and reassociation reactions occur in the picomolar and nanomolar range respectively. The cytolytic activity of L-M cells correlates with oligomeric-TNF levels after incubation at picomolar concentrations. Moreover, isolated oligomeric TNF was cytotoxic towards L-M cells, whereas monomeric TNF was virtually inactive. In conclusion, the results suggest that bioactive oligomeric TNF is unstable at picomolar levels and slowly converts into inactive monomers, supporting the hypothesis that quaternary-structure changes in TNF may contribute to the fine regulation of TNF cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1622406      PMCID: PMC1132625          DOI: 10.1042/bj2840905

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  24 in total

1.  The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding.

Authors:  M J Eck; S R Sprang
Journal:  J Biol Chem       Date:  1989-10-15       Impact factor: 5.157

2.  Efficient purification of recombinant human tumor necrosis factor beta from Escherichia coli yields biologically active protein with a trimeric structure that binds to both tumor necrosis factor receptors.

Authors:  H J Schoenfeld; B Poeschl; J R Frey; H Loetscher; W Hunziker; A Lustig; M Zulauf
Journal:  J Biol Chem       Date:  1991-02-25       Impact factor: 5.157

Review 3.  Cachectin/tumour necrosis factor.

Authors:  K J Tracey; H Vlassara; A Cerami
Journal:  Lancet       Date:  1989-05-20       Impact factor: 79.321

4.  The active form of tumor necrosis factor is a trimer.

Authors:  R A Smith; C Baglioni
Journal:  J Biol Chem       Date:  1987-05-25       Impact factor: 5.157

5.  An endotoxin-induced serum factor that causes necrosis of tumors.

Authors:  E A Carswell; L J Old; R L Kassel; S Green; N Fiore; B Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

6.  Bioactive and inactive forms of tumor necrosis factor-alpha in spinal fluid from patients with meningitis.

Authors:  B Møller; S C Mogensen; P Wendelboe; K Bendtzen; C M Petersen
Journal:  J Infect Dis       Date:  1991-04       Impact factor: 5.226

Review 7.  Tumor necrosis factor alpha: a multifaceted peptide hormone.

Authors:  M G Rosenblum; N J Donato
Journal:  Crit Rev Immunol       Date:  1989       Impact factor: 2.214

Review 8.  The biology of cachectin/TNF--a primary mediator of the host response.

Authors:  B Beutler; A Cerami
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

9.  Reversible subunit dissociation of tumor necrosis factor during hydrophobic interaction chromatography.

Authors:  M G Kunitani; R L Cunico; S J Staats
Journal:  J Chromatogr       Date:  1988-06-29

10.  Crystallization of trimeric recombinant human tumor necrosis factor (cachectin).

Authors:  M J Eck; B Beutler; G Kuo; J P Merryweather; S R Sprang
Journal:  J Biol Chem       Date:  1988-09-15       Impact factor: 5.157

View more
  34 in total

1.  Production of polyclonal antibodies to feline tumor necrosis factor.

Authors:  C M Otto; F Niagro; R A McGraw; C A Rawlings
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

2.  Thiolated recombinant human tumor necrosis factor-alpha protects against Plasmodium berghei K173-induced experimental cerebral malaria in mice.

Authors:  N S Postma; R C Hermsen; D J Crommelin; W M Eling; J Zuidema
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  Automated Analysis of Single-Molecule Photobleaching Data by Statistical Modeling of Spot Populations.

Authors:  Clarissa Liesche; Kristin S Grussmayer; Michael Ludwig; Stefan Wörz; Karl Rohr; Dirk-Peter Herten; Joël Beaudouin; Roland Eils
Journal:  Biophys J       Date:  2015-12-01       Impact factor: 4.033

4.  Patterns of disease activity in multiple sclerosis patients: a study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups.

Authors:  M Rovaris; D Barnes; N Woodrofe; G H du Boulay; J W Thorpe; A J Thompson; W I McDonald; D H Miller
Journal:  J Neurol       Date:  1996-07       Impact factor: 4.849

5.  Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability.

Authors:  Mohammad Fallahi-Sichani; JoAnne L Flynn; Jennifer J Linderman; Denise E Kirschner
Journal:  J Immunol       Date:  2012-02-29       Impact factor: 5.422

6.  Recognition of human tumor necrosis factor α (TNF-α) by therapeutic antibody fragment: energetics and structural features.

Authors:  Jaka Marušič; Črtomir Podlipnik; Simona Jevševar; Drago Kuzman; Gorazd Vesnaver; Jurij Lah
Journal:  J Biol Chem       Date:  2012-01-19       Impact factor: 5.157

7.  Tumor Necrosis Factor-α Trimer Disassembly and Inactivation via Peptide-Small Molecule Synergy.

Authors:  James W Checco; Geoffrey A Eddinger; Nicholas J Rettko; Alexander R Chartier; Samuel H Gellman
Journal:  ACS Chem Biol       Date:  2020-07-14       Impact factor: 5.100

8.  Higher order structures of Adalimumab, Infliximab and their complexes with TNFα revealed by electron microscopy.

Authors:  Bich Ngoc Tran; Siew Leong Chan; Chloe Ng; Jian Shi; Ivan Correia; Czeslaw Radziejewski; Paul Matsudaira
Journal:  Protein Sci       Date:  2017-11-14       Impact factor: 6.725

9.  Anti-inflammatory and Antioxidant Effects of Captopril Compared to Methylprednisolone in L-Arginine-Induced Acute Pancreatitis.

Authors:  Nahla E El-Ashmawy; Naglaa F Khedr; Hoda A El-Bahrawy; Omnia B Hamada
Journal:  Dig Dis Sci       Date:  2018-03-29       Impact factor: 3.199

10.  Identification of key processes that control tumor necrosis factor availability in a tuberculosis granuloma.

Authors:  Mohammad Fallahi-Sichani; Matthew A Schaller; Denise E Kirschner; Steven L Kunkel; Jennifer J Linderman
Journal:  PLoS Comput Biol       Date:  2010-05-06       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.